Abstract
Mycobacterium tuberculosis (Mtb) remains the deadliest bacterial pathogen worldwide, causing an estimated 1.7 million deaths in 2004 among an infected population of approximately 2 billion people, according to the World Health Organization (WHO). Therapeutic options are limited to a few drugs that are becoming increasingly ineffective. Multidrug-resistant (MDR) Mtb strains are prevalent globally, fueled by inadequate patient compliance of drug intake. Recently, a high incidence of extensively drug-resistant (XDR) strains resistant to all currently used drugs was reported among patients with the human immunodeficiency virus (HIV) in KwaZulu Natal, South Africa [1]. The high mortality rate and short survival time of patients with XDR Mtb was especially alarming. The emergence of XDR mycobacteria emphasizes the urgent need for the identification of novel targets and development of new drugs. New potential drug targets exist in the Mtb respiratory chain. Certain classes of drugs have long been shown to exert significant tuberculocidal activity, such as the phenothiazines [2, 3]. Phenothiazines inhibit one of the key enzymes of the respiratory chain; type II NADH:menaquinone oxidoreductase or NDH-2 [4]. The effectiveness of this class of drugs against Mtb justifies further research into the respiratory chain, with the aim of elucidating its physiologic roles in in vitro and in vivo survival, and discovering new (sub)classes of drugs that can safely serve as inhibitors for clinical use. In this chapter, we critically review the recent advances in this field, with particular emphasis on NDH-2, and underscore the kinds of research further needed for drug development.
Keywords: NADH, oxidoreductase, tuberculosis, mycobacteria, drug, dormancy, inhibition, phenothiazine
Infectious Disorders - Drug Targets
Title: Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
Volume: 7 Issue: 2
Author(s): J. S. Teh, T. Yano and H. Rubin
Affiliation:
Keywords: NADH, oxidoreductase, tuberculosis, mycobacteria, drug, dormancy, inhibition, phenothiazine
Abstract: Mycobacterium tuberculosis (Mtb) remains the deadliest bacterial pathogen worldwide, causing an estimated 1.7 million deaths in 2004 among an infected population of approximately 2 billion people, according to the World Health Organization (WHO). Therapeutic options are limited to a few drugs that are becoming increasingly ineffective. Multidrug-resistant (MDR) Mtb strains are prevalent globally, fueled by inadequate patient compliance of drug intake. Recently, a high incidence of extensively drug-resistant (XDR) strains resistant to all currently used drugs was reported among patients with the human immunodeficiency virus (HIV) in KwaZulu Natal, South Africa [1]. The high mortality rate and short survival time of patients with XDR Mtb was especially alarming. The emergence of XDR mycobacteria emphasizes the urgent need for the identification of novel targets and development of new drugs. New potential drug targets exist in the Mtb respiratory chain. Certain classes of drugs have long been shown to exert significant tuberculocidal activity, such as the phenothiazines [2, 3]. Phenothiazines inhibit one of the key enzymes of the respiratory chain; type II NADH:menaquinone oxidoreductase or NDH-2 [4]. The effectiveness of this class of drugs against Mtb justifies further research into the respiratory chain, with the aim of elucidating its physiologic roles in in vitro and in vivo survival, and discovering new (sub)classes of drugs that can safely serve as inhibitors for clinical use. In this chapter, we critically review the recent advances in this field, with particular emphasis on NDH-2, and underscore the kinds of research further needed for drug development.
Export Options
About this article
Cite this article as:
J. S. Teh , T. Yano and H. Rubin , Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001781
DOI https://dx.doi.org/10.2174/187152607781001781 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Tubercular and Anti-Inflammatory Activities of Azetidin-2-One Derivatives and Their Effects on the Activity of Phospholipase A2
Medicinal Chemistry Design, Synthesis and Anti-tuberculosis Activity of Hydrazones and N-acylhydrazones Containing Vitamin B6 and Different Heteroaromatic Nucleus
Letters in Drug Design & Discovery Growth Regulation in the Mycobacterial Cell
Current Molecular Medicine Novel Drug Delivery Magnetite Nano-systems Used in Antimicrobial Therapy
Current Organic Chemistry A Guide to Treatment of Sarcoidosis
Current Drug Therapy Tuberculous Tenosynovitis of the Wrist: A Report of Two Cases with Special Reference to Magnetic Resonance Findings
Current Medical Imaging Peptidylprolyl Cis / Trans Isomerases (Immunophilins): Biological Diversity - Targets - Functions
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Copper (II) – HisAibGly Complex and Its Superoxide Dismutase Activity (Suplementary Material)
Protein & Peptide Letters Nanoparticles and Immune Cells
Current Pharmaceutical Design Targeting Enzymes with Phosphonate-Based Inhibitors: Mimics of Tetrahedral Transition States and Stable Isosteric Analogues of Phosphates
Current Enzyme Inhibition Using Genomics for Natural Product Structure Elucidation
Current Topics in Medicinal Chemistry Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface [Hot topic: Carbohydrates (Executive Editor: Istvan Toth)]
Mini-Reviews in Medicinal Chemistry Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Infectious Disorders - Drug Targets Synthesis and Biological Evaluation of Some New Indolizine Derivatives as Antitumoral Agents
Letters in Drug Design & Discovery Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research